Effects of inhaled nitric oxide on platelet-activating factor-induced pulmonary hypertension in dogs

Acta Anaesthesiologica Scandinavica

Volumn 42, Issue 3, 1998, Pages 358-368

  Yamada, T ^a   Yukioka, H ^a   Hayashi, M ^a   Asada, A ^a   Inoue, M ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Gases; Lung(s):pulmonary hypertension; Nitric oxide; Non anesthetics; Pharmacology:N(G) nitro L arginine, platelet activating factor, U46619

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; METHEMOGLOBIN; N(G) NITROARGININE; NITRATE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; NITRITE; PENTOBARBITAL; THROMBOCYTE ACTIVATING FACTOR; THROMBOXANE A2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOG; DRUG EFFECT; ENDOTOXEMIA; FEMALE; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG ARTERY PRESSURE; LUNG BLOOD VESSEL; LUNG HEMODYNAMICS; MALE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; VASODILATATION;

EID: 0031951854     PISSN: 00015172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-6576.1998.tb04930.x     Document Type: Article

References (35)

1. Änggård E. Nitric oxide: mediator, murderer, and medicine. Lancet 1994: 343: 1199-1206.
2. Rossaint R, Falke KJ, López F, Slama K, Pison U, Zapol WM. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 1993: 328: 399-405.
3. Bigatello LM, Hurford WE, Kacmarek RM, Roberts JD, Zapol WM. Prolonged inhalation of low concentrations of nitric oxide in patients with severe adult respiratory distress syndrome. Anesthesiology 1994: 80: 761-770.
4. Gerlach H, Pappert D, Lewandowski K, Rossaint R, Falke KJ. Long-term inhalation with evaluated low doses of nitric oxide for selective improvement of oxygenation in patients with adult respiratory distress syndrome. Intensive Care Med 1993: 19: 443-449.
5. Putensen C, Räsänen J, Downs JB. Effect of endogenous and inhaled nitric oxide on the ventilation-perfusion relationships in oleic-acid lung injury. Am J Respir Crit Care Med 1994: 150: 330-336.
6. Dyar O, Young JD, Xiong L, Howell S, Johns E. Dose-response relationship for inhaled nitric oxide in experimental pulmonary hypertension in sheep. Br J Anaesth 1993: 71: 702-708.
7. Frostell C, Fratacci MD, Wain JC, Jones R, Zapol WM. Inhaled nitric oxide: A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation 1991: 83: 2038-2047.
8. Fratacci MD, Frostell C, Chen TY, Wain JC, Robinson DR, Zapol WM. Inhaled nitric oxide. A selective pulmonary vasodilator of heparin-protamine vasoconstriction in sheep. Anesthesiology 1991: 75: 990-999.
9. Lu Q, Mourgeon E, Law-Koune JD, Roche S, Vézinet C, Abdennour L et al. Dose-response curves of inhaled nitric oxide with and without intravenous almitrine in nitric oxide-responding patients with acute respiratory distress syndrome. Anesthesiology 1995: 83: 929-943.
10. Lowson SM, Rich GF, McArdle PA, Jaidev J, Morris GN. The response to varying concentrations of inhaled nitric oxide in patients with acute respiratory distress syndrome. Anesth Analg 1996: 82: 574-581.
11. Barnes PJ, Henson PM. Platelet-activating factor. In: Crystal RG, West JB, eds. The lung. New York: Raven Press, 1991: 49-59.
12. Mózes T, Zijlstra FJ, Heiligers JPC, Tak CJAM, Ben-Efraim S, Bonta VL et al. Sequential release of tumor necrosis factor, platelet activating factor and eicosanoids during endotoxin shock in anaesthetized pigs; protective effects of indomethacin. Br J Pharmacol 1991: 104: 691-699.
13. Bessin P, Bonnet J, Apffel D, Soulard C, Desgroux L, Pelas I et al. Acute circulatory collapse caused by platelet-activating factor (PAF-Acether) in dogs. Eur J Pharmacol 1983: 86: 403-413.
14. Kenzora JL, Pérez JE, Bergmann SR, Lange LG. Effects of acetyl glyceryl ether phosphorylcholine (platelet-activating factor) on ventricular preload, afterload, and contractility in dogs. J Clin Invest 1984: 74: 1193-1203.
15. Laurindo FRM, Goldstein RE, Davenport NJ, Ezra D, Feuerstein GZ. Mechanisms of hypotension produced by platelet-activating factor. J Appl Physiol 1989: 66: 2681-2690.
16. Yamanaka S, Miura K, Yukimura T, Okumura M, Yamamoto K. Putative mechanism of hyportensive action of platelet-activating factor in dogs. Circ Res 1992: 70: 893-901.
17. 4 in the rat lung. J Appl Physiol 1992: 73: 955-961.
18. Bellan JA, Minkes RK, Hood JS, McMahon TJ, Higuera TR, Nossaman BD et al. Analysis of pulmonary and systemic vascular resposes to platelet-activating factor in the cat. Am J Physiol 1992: 263: H234-H243.
19. Szabó C, Wu C, Mitchell JA, Gross SS, Thiemermann C, Vane JR. Platelet-activating factor contributes to the induction of nitric oxide synthase by bacterial lipopolysaccharide. Circ Res 1993: 73: 991-999.
20. Gao Y, Zhou H, Raj JU. PAF induces relaxation of pulmonary arteries but contraction of pulmonary veins in the ferret. Am J Physiol 1995: 269: H704-H709.
21. G-nitro-L-arginine on shock induced by endotoxin and by platelet activating factor in dogs. Eur J Pharmacol 1993: 250: 465-467.
22. Albertini M, Clement MG. In pigs, inhaled nitric oxide (NO) counterbalances PAF-induced pulmonary hypertension. Prostaglandins Leukot Essent Fatty Acids 1994: 51: 357-362.
23. 15N]nitrate in biological fluids. Anal Biochem 1982: 126: 131-138.
24. Rossaint R, Slama K, Steudel W, Gerlach H, Pappert D, Veit S et al. Effects of inhaled nitric oxide on right ventricular function in severe acute respiratory distress syndrome. Intensive Care Med 1995: 21: 197-203.
25. Bocchi EA, Bacal F, Auler JOC, Carmone MJC, Bellotti G, Pileggi F. Inhaled nitric oxide leading to pulmonary edema in stable severe heart failure. Am J Cardiol 1994: 74: 70-72.
26. Shibamoto T, Yamaguchi Y, Hayashi T, Saeki Y, Kawamoto M, Koyama S. PAF increases capillary pressure but not vascular permeability in isolated blood-perfused canine lungs. Am J Physiol 1993: 264: H1454-H1459.
27. Hamasaki Y, Mojarad M, Saga T, Tai H, Said SI. Platelet-activating factor raises airway and vascular pressures and induces edema in lungs perfused with platelet-free solution. Am Rev Respir Dis 1984: 129: 742-746.
28. Benzing A, Geiger K. Inhaled nitric oxide lowers pulmonary capillary pressure and changes longitudinal distribution of pulmonary vascular resistance in patients with acute lung injury. Acta Anaesthesiol Scand 1994: 38: 640-645.
29. Klemm P, Thiemermann C, Winklmaier G, Martorana PA, Henning R. Effects of nitric oxide synthase inhibition combined with nitric oxide inhalation in a porcine model of endotoxin shock. Br J Pharmacol 1995: 114: 363-368.
30. 2 mimetic) induces airflow obstruction and airway plasma extravasation in the guinea pig: The role of histamine, cyclooxygenase metabolites, leukotrienes and PAF. J Pharmacol Exp Ther 1996: 278: 268-276.
31. ω-nitro-L-arginine and pulmonary vascular pressure-flow relationship in conscious dogs. Am J Physiol 1992: 262: H1331-H1337.
32. Puybasset J, Rouby JJ, Mourgeon E, Cluzel P, Souhil Z, Law-Koune JD et al. Factors influencing cardiopulmonary effects of inhaled nitric oxide in acute respiratory failure. Am J Respir Crit Care Med 1995: 152: 318-328.
33. Davidson CA, Kaminski PM, Wu M, Wolin MS. Nitrogen dioxide causes pulmonary arterial relaxation via thiol nitrosation and NO formation. Am J Physiol 1996: 270: H1038-H1043.
34. Ochoa JB, Udekwu AO, Billiar TR, Curran RD, Cerra FB, Simmons RL et al. Nitrogen oxide levels in patients after trauma and during sepsis. Ann Surg 1991: 214: 621-626.
35. Young JD, Sear JW, Valvini EM. Kinetics of methaemoglobin and serum nitrogen oxide production during inhalation of nitric oxide in volunteers. Br J Anaesth 1996: 76: 652-656.